0001193125-26-278048.txt : 20260623 0001193125-26-278048.hdr.sgml : 20260623 20260622201320 ACCESSION NUMBER: 0001193125-26-278048 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260623 DATE AS OF CHANGE: 20260622 EFFECTIVENESS DATE: 20260623 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tempest Therapeutics, Inc. CENTRAL INDEX KEY: 0001544227 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 451472564 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-588192 FILM NUMBER: 261108654 BUSINESS ADDRESS: STREET 1: 2000 SIERRA POINT PARKWAY STREET 2: SUITE 400 CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 415-798-8589 MAIL ADDRESS: STREET 1: 2000 SIERRA POINT PARKWAY STREET 2: SUITE 400 CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: Millendo Therapeutics, Inc. DATE OF NAME CHANGE: 20181207 FORMER COMPANY: FORMER CONFORMED NAME: OvaScience, Inc. DATE OF NAME CHANGE: 20120308 D 1 primary_doc.xml X0708 D LIVE 0001544227 Tempest Therapeutics, Inc. 2000 SIERRA POINT PARKWAY, SUITE 400 BRISBANE CA CALIFORNIA 94005 415-798-8589 DELAWARE None Millendo Therapeutics, Inc. OvaScience, Inc. Corporation true Matthew Angel Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane CA CALIFORNIA 94005 Executive Officer Director President and Chief Executive Officer Justin Trojanowski Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane CA CALIFORNIA 94005 Executive Officer Vice President, Finance, Principal Financial Officer and Corporate Secretary John David Yee Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane CA CALIFORNIA 94005 Director William Drake Richey Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane CA CALIFORNIA 94005 Director Biotechnology Decline to Disclose 06b false 2026-05-29 true true true true true Common Stock Purchase Warrant, including underlying shares of common stock true 0 4056552 4056552 0 Offering amount for common stock purchase warrant does not include proceeds of $2028276 for warrant exercise. (amounts rounded) false 1 0 0 0 false Tempest Therapeutics, Inc. /s/ Matthew Angel Matthew Angel President and Chief Executive Officer 2026-06-22